Divisions of Clinical Geriatrics, Department of Neurobiology Care Sciences and Society, Karolinska Institutete, Stockholm, Sweden.
Theme Inflammation and Aging, Karolinska University Hospital Stockholm, Stockholm, Sweden.
Eur J Neurol. 2022 Dec;29(12):3580-3589. doi: 10.1111/ene.15536. Epub 2022 Sep 11.
The aim was to investigate the effect of APOE ε4 allele on cognitive decline in adAD. Presence of the APOE ε4 allele reduces age of symptom onset, increases disease progression, and lowers cognitive performance in sporadic Alzheimer's disease (AD), while the impact of the APOE ε4 allele in autosomal-dominant AD (adAD) is incompletely known.
Mutation carriers (MCs; n = 39) and non-carriers (NCs; n = 40) from six adAD families harbouring a mutation in the APP (28 MCs and 25 NCs) or the PSEN1 genes (11 MCs and 15 NCs) underwent repeated cognitive assessments. A timeline of disease course was defined as years to expected age of clinical onset (YECO) based on history of disease onset in each family. The MC and NC groups were comparable with regard to demographics and prevalence of the APOE ε4 allele. The relationship between cognitive decline and YECO, YECO , education, APOE, and APOE-by-YECO interaction was analysed using linear mixed-effects models.
The trajectory of cognitive decline was significantly predicted by linear and quadratic YECO and education in MCs and was determined by age and education in NCs. Adding APOE ε4 allele (presence/absence) as a predictor did not change the results in the MC and NC groups. The outcome also remained the same for MCs and NCs after adding the APOE-by-YECO interaction as a predictor. Analyses of APP and PSEN1 MCs separately showed favourable APOE-by-YECO interaction in APP (less steep decline) and unfavourable interaction in PSEN1 (steeper decline), linked to the APOE ε4 allele.
The APOE ε4 allele influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with adAD, indicating a possible antagonistic pleiotropy.
本研究旨在探讨 APOE ε4 等位基因对 AD 认知衰退的影响。APOE ε4 等位基因的存在会降低散发性阿尔茨海默病(AD)的发病年龄,加快疾病进展,降低认知表现,而其在常染色体显性 AD(adAD)中的影响尚不完全清楚。
来自六个携带 APP(28 名 MC 和 25 名 NC)或 PSEN1 基因突变的 adAD 家族的突变携带者(MCs;n=39)和非携带者(NCs;n=40)接受了多次认知评估。根据每个家族的疾病发病史,定义疾病过程的时间线为 YECO 预期年龄(YECO)的年数。MC 组和 NC 组在人口统计学特征和 APOE ε4 等位基因的流行率方面具有可比性。使用线性混合效应模型分析认知衰退与 YECO、YECO、教育、APOE 和 APOE-by-YECO 相互作用之间的关系。
MC 组的认知衰退轨迹明显受线性和二次 YECO 和教育的预测,而 NC 组则由年龄和教育决定。在 MC 和 NC 组中,添加 APOE ε4 等位基因(存在/缺失)作为预测因子不会改变结果。在添加 APOE-by-YECO 相互作用作为预测因子后,MC 和 NC 组的结果也保持不变。对 APP 和 PSEN1 MC 分别进行分析显示,APOE-by-YECO 相互作用在 APP 中有利(下降较缓),在 PSEN1 中不利(下降较陡),这与 APOE ε4 等位基因有关。
APOE ε4 等位基因对 adAD 中携带 APP 和 PSEN1 突变的 MCs 的认知衰退有积极影响,对 PSEN1 突变的 MCs 有消极影响,表明可能存在拮抗的多效性。